NCT07623200

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2026-07-31Est. Completion: 2029-06-15

Enrollment target: 426 participants

Contact

Incyte Corporation Call Center (US)medinfo@incyte.com 1.855.463.3463

Incyte Corporation Call Center (ex-US)eumedinfo@incyte.com +800 00027423

Other microbiome trials you might be interested in

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPhase 1Recruiting

Polycythemia Vera (PV)Myelofibrosis (MF)Myeloproliferative Neoplasms (MPNs)Post-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia MyelofibrosisPrimary Myelofibrosis (PMF)

This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmaco…

Denver, United StatesEst. completion Apr 2028

View Trial →

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)Phase 3Recruiting

Essential Thrombocythemia

The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreducti…

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.